Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

被引:0
作者
Philip J. Mease
Alexis Ogdie
John Tesser
Natalie J. Shiff
Iris Lin
Soumya D. Chakravarty
Michael Kelleman
Rhiannon Dodge
Robert R. McLean
Aaron Broadwell
Arthur Kavanaugh
Joseph F. Merola
机构
[1] Swedish Medical Center/Providence St. Joseph Health and University of Washington,Brigham and Women’s Hospital
[2] University of Pennsylvania School of Medicine,undefined
[3] Arizona Arthritis and Rheumatology Associates,undefined
[4] P.C.,undefined
[5] Janssen Scientific Affairs,undefined
[6] LLC,undefined
[7] University of Saskatchewan,undefined
[8] Drexel University College of Medicine,undefined
[9] CorEvitas,undefined
[10] LLC,undefined
[11] Rheumatology and Osteoporosis Specialists,undefined
[12] University of California San Diego,undefined
[13] Harvard Medical School,undefined
来源
Rheumatology and Therapy | 2023年 / 10卷
关键词
Psoriatic arthritis; Biologics; Guselkumab; Real-world evidence;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1479 / 1501
页数:22
相关论文
共 106 条
[1]  
Armstrong AW(2021)Psoriasis prevalence in adults in the United States JAMA Dermatol 157 940-946
[2]  
Mehta MD(2019)Psoriatic arthritis: what is happening at the joint? Rheumatol Ther 6 305-315
[3]  
Schupp CW(2020)EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update Ann Rheum Dis 79 700-712
[4]  
Gondo GC(2022)Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021 Nat Rev Rheumatol 18 465-479
[5]  
Bell SJ(2016)Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis Arthritis Rheumatol 68 1060-1071
[6]  
Griffiths CEM(2020)Assessment of the many faces of PsA: single and composite measures in PsA clinical trials Rheumatology (Oxford) 59 i29-i36
[7]  
Belasco J(2019)Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis Arthritis Rheumatol 71 5-32
[8]  
Wei N(2021)Guselkumab: the first selective IL-23 inhibitor for active psoriatic arthritis in adults Expert Rev Clin Immunol 17 5-13
[9]  
Gossec L(2020)Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial Lancet 395 1115-1125
[10]  
Baraliakos X(2020)Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial Lancet 395 1126-1136